Related Experiment Video
Updated: Aug 17, 2026

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
Monitoring the safety of licensed medicines
Alasdair Breckenridge1, Kent Woods, June Raine
1Medicines and Healthcare Products Regulatory Agency London UK, Market Towers, 1 Nine Elms Lane, London SW8 5NQ, UK. Alasdair.Breckenridge@mhra.gsi.gov.uk
Abstract:
The withdrawal of the selective cyclooxygenase 2 inhibitor rofecoxib owing to cardiovascular side effects ignited debate about the need for major changes to current mechanisms for post-marketing surveillance (PMS) of drug safety. Here, we discuss the current mechanisms, whether they are being used appropriately, and consider the need for changes to regulatory systems.
Related Concept Videos
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Regulation
Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring: Drug Analysis Methods
Drug Control Governance: Regulatory Bodies and Their Impact
Pharmaceutical Poisoning: Potential Scenarios

